Sorrento Therapeutics Inc. is a clinical and commercial stage biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs. It focuses on cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases by leveraging proprietary technologies such as the G-MAB antibody library and targeted delivery modalities like CAR-T and DAR-T cell therapies. The company also develops pain management solutions, including resiniferatoxin and SEMDEXA, and has been involved in COVID-19 therapeutic and vaccine development. Sorrento Therapeutics operates across multiple sectors in the healthcare industry, contributing to advancements in biotechnology and pharmaceuticals.